• Je něco špatně v tomto záznamu ?

Real-World Safety and Efficacy Outcomes with Abiraterone Acetate Plus Prednisone or Prednisolone as the First- or Second-Line Treatment for Metastatic Castration-Resistant Prostate Cancer: Data from the Prostate Cancer Registry

A. Bjartell, N. Lumen, P. Maroto, T. Paiss, F. Gomez-Veiga, A. Birtle, G. Kramer, E. Kalinka, D. Spaëth, S. Feyerabend, V. Matveev, F. Lefresne, M. Lukac, R. Wapenaar, L. Costa, S. Chowdhury

. 2021 ; 16 (3) : 357-367. [pub] 20210407

Jazyk angličtina Země Francie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22004428
E-zdroje Online Plný text

NLK ProQuest Central od 2006-01-01 do Před 1 rokem
Medline Complete (EBSCOhost) od 2006-01-01 do Před 1 rokem
Nursing & Allied Health Database (ProQuest) od 2006-01-01 do Před 1 rokem
Health & Medicine (ProQuest) od 2006-01-01 do Před 1 rokem
Family Health Database (ProQuest) od 2006-01-01 do Před 1 rokem

Odkazy

PubMed 33826036
DOI 10.1007/s11523-021-00807-4
Knihovny.cz E-zdroje

BACKGROUND: Despite standard-of-care androgen-deprivation therapy and an increasing number of treatment options, the mortality rate for prostate cancer remains high. Progress to metastatic castration-resistant prostate cancer (mCRPC) necessitates additional treatments. Abiraterone acetate plus prednisone or prednisolone (AAP) prolongs survival in chemotherapy-naive and docetaxel-experienced patients. OBJECTIVE: To evaluate the real-world safety and efficacy of AAP as first-line and second-line [post-docetaxel only (AAP-PD)] treatment in patients with mCRPC. PATIENTS AND METHODS: The Prostate Cancer Registry (PCR) was a prospective, international, observational study of patients with mCRPC in routine clinical practice. Men aged ≥ 18 years with confirmed mCRPC were included. Baseline characteristics, safety (treatment-emergent adverse events, treatment-emergent severe adverse events), and efficacy [progression-free survival (PFS) and overall survival (OS)] were analyzed. RESULTS: At baseline, patients who received first-line AAP (n = 754) were generally older than patients who received AAP-PD (n = 354); median age was 76 years and 70 years, respectively. However, the rate of visceral metastasis was higher in the AAP-PD cohort than in the AAP cohort (17.7% vs. 9.6%, respectively). Demographics and disease characteristics of patients with baseline cardiovascular disease were similar to those of the overall registry population. Efficacy outcomes were similar for all patients, regardless of the line of AAP therapy. For first-line AAP and AAP-PD, respectively, the median PFS was 8.9 and 5.8 months for all patients and 9.1 and 6.0 months for patients with cardiovascular comorbidities; median OS was 27.1 and 23.4 months for all patients, and 27.4 and 23.1 months for patients with cardiovascular comorbidities. There were no unexpected adverse events in any patient subgroup. CONCLUSIONS: These real-world data complement the findings from randomized controlled trials, indicating that first- and second-line AAP is well tolerated and effective in patients with mCRPC, including those with underlying CV comorbidities. TRIAL REGISTRATION NUMBER: NCT02236637, registered 8 September 2014.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22004428
003      
CZ-PrNML
005      
20220127145246.0
007      
ta
008      
220113s2021 fr f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s11523-021-00807-4 $2 doi
035    __
$a (PubMed)33826036
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a fr
100    1_
$a Bjartell, Anders $u Department of Urology, Skåne University Hospital Malmö, Jan Waldenströms gata 5, SE 205 02, Malmö, Sweden. anders.bjartell@med.lu.se $u Department of Translational Medicine, Medical Faculty, Lund University, Malmö, Sweden. anders.bjartell@med.lu.se
245    10
$a Real-World Safety and Efficacy Outcomes with Abiraterone Acetate Plus Prednisone or Prednisolone as the First- or Second-Line Treatment for Metastatic Castration-Resistant Prostate Cancer: Data from the Prostate Cancer Registry / $c A. Bjartell, N. Lumen, P. Maroto, T. Paiss, F. Gomez-Veiga, A. Birtle, G. Kramer, E. Kalinka, D. Spaëth, S. Feyerabend, V. Matveev, F. Lefresne, M. Lukac, R. Wapenaar, L. Costa, S. Chowdhury
520    9_
$a BACKGROUND: Despite standard-of-care androgen-deprivation therapy and an increasing number of treatment options, the mortality rate for prostate cancer remains high. Progress to metastatic castration-resistant prostate cancer (mCRPC) necessitates additional treatments. Abiraterone acetate plus prednisone or prednisolone (AAP) prolongs survival in chemotherapy-naive and docetaxel-experienced patients. OBJECTIVE: To evaluate the real-world safety and efficacy of AAP as first-line and second-line [post-docetaxel only (AAP-PD)] treatment in patients with mCRPC. PATIENTS AND METHODS: The Prostate Cancer Registry (PCR) was a prospective, international, observational study of patients with mCRPC in routine clinical practice. Men aged ≥ 18 years with confirmed mCRPC were included. Baseline characteristics, safety (treatment-emergent adverse events, treatment-emergent severe adverse events), and efficacy [progression-free survival (PFS) and overall survival (OS)] were analyzed. RESULTS: At baseline, patients who received first-line AAP (n = 754) were generally older than patients who received AAP-PD (n = 354); median age was 76 years and 70 years, respectively. However, the rate of visceral metastasis was higher in the AAP-PD cohort than in the AAP cohort (17.7% vs. 9.6%, respectively). Demographics and disease characteristics of patients with baseline cardiovascular disease were similar to those of the overall registry population. Efficacy outcomes were similar for all patients, regardless of the line of AAP therapy. For first-line AAP and AAP-PD, respectively, the median PFS was 8.9 and 5.8 months for all patients and 9.1 and 6.0 months for patients with cardiovascular comorbidities; median OS was 27.1 and 23.4 months for all patients, and 27.4 and 23.1 months for patients with cardiovascular comorbidities. There were no unexpected adverse events in any patient subgroup. CONCLUSIONS: These real-world data complement the findings from randomized controlled trials, indicating that first- and second-line AAP is well tolerated and effective in patients with mCRPC, including those with underlying CV comorbidities. TRIAL REGISTRATION NUMBER: NCT02236637, registered 8 September 2014.
650    _2
$a abirateron $x farmakologie $x terapeutické užití $7 D000069501
650    _2
$a senioři $7 D000368
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a prednison $x farmakologie $x terapeutické užití $7 D011241
650    _2
$a nádory prostaty rezistentní na kastraci $x farmakoterapie $7 D064129
650    _2
$a registrace $7 D012042
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Lumen, Nicolaas $u Department of Urology, Ghent University Hospital, Ghent, Belgium
700    1_
$a Maroto, Pablo $u Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain
700    1_
$a Paiss, Thomas $u Urologie team Ulm, Ulm, Germany
700    1_
$a Gomez-Veiga, Francisco $u Urology Department and Kidney Transplant Unit, Translational Research Group of Urology GITUR-IBSAL, Salamanca University Hospital, Salamanca, Spain
700    1_
$a Birtle, Alison $u Royal Preston Hospital, Preston, UK
700    1_
$a Kramer, Gero $u Department of Urology, Medical University of Vienna, Vienna, Austria
700    1_
$a Kalinka, Ewa $u Clinic of Oncology, Polish Mother's Memorial Hospital, Research Institute, Lodz, Poland
700    1_
$a Spaëth, Dominique $u Centre d'Oncologie de Gentilly, Nancy, France
700    1_
$a Feyerabend, Susan $u Studienpraxis Urologie, Nürtingen, Germany
700    1_
$a Matveev, Vsevolod $u N.N. Blokhin National Cancer Research Center, Moscow, Russia
700    1_
$a Lefresne, Florence $u EMEA Oncology, Janssen Pharmaceutica N.V., Beerse, Belgium
700    1_
$a Lukac, Martin $u Parexel International Czech Republic s.r.o, on behalf of Janssen Pharmaceutica N.V., Beerse, Belgium
700    1_
$a Wapenaar, Robert $u Janssen-Cilag B.V., Breda, The Netherlands
700    1_
$a Costa, Luis $u Oncology Division, Faculdade de Medicina, Hospital de Santa Maria, Instituto de Medicina Molecular, Universidade de Lisboa, Lisbon, Portugal
700    1_
$a Chowdhury, Simon $u Guy's and St Thomas' NHS Foundation Trust and Sarah Cannon Research Institute, London, UK
773    0_
$w MED00189571 $t Targeted oncology $x 1776-260X $g Roč. 16, č. 3 (2021), s. 357-367
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33826036 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127145242 $b ABA008
999    __
$a ok $b bmc $g 1751793 $s 1155577
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 16 $c 3 $d 357-367 $e 20210407 $i 1776-260X $m Targeted oncology $n Target Oncol $x MED00189571
LZP    __
$a Pubmed-20220113

Najít záznam

Citační ukazatele

Možnosti archivace